Changes between baseline and week 24 relative to the EULAR response
| Median changes from baseline to week 24 | Second TNFi | Other biologic | Tocilizumab | |||
| Responders (n=64) | Non-responders (n=31) | Responders (n=76) | Non-responders (n=30) | Responders (n=42) | Non-responders (n=5) | |
| ApoA1 (IQR) (g/L) | 0.09 (−0.05 to 0;21) | −0.08 (−0.19 to 0.04) | 0.06 (−0.07 to 0.26) | −0.05 (−0.19 to 0.1) | 0.13 (−0.06 to 0.31) | −0.18 (−0.27 to −0.05) |
| p=0.0004 | p=0.02 | p=0.032 | ||||
| ApoB100 (IQR) (g/L) | −0.01 (−0.1 to 0.08) | −0.03 (−0.09 to 0.08) | 0.04 (−0.09 to 0.13) | 0.02 (−0.06 to 0.11) | 0.08 (−0.15 to 0.23) | 0.08 (0.07 to 0.11) |
| p=0.79 | p=0.55 | p=0.82 | ||||
| ApoB100/ApoA1 ratio | −0.03 (−0.09 to 0.04) | 0.03 (−0.05 to 0.06) | 0.0001 (−0.07 to 0.08) | 0.04 (−0.07 to 0.09) | 0.0001 (−0.07 to 0.08) | 0.12 (0.05 to 0.13) |
| p=0.057 | p=0.27 | p=0.03 | ||||
| Lp(a) (IQR) (g/L) | −0.01 (−0.03 to 0.01) | 0 (−0.01 to 0.02) | −0.01 (−0.06 to 0.01) | 0 (−0.02 to 0.04) | −0.05 (−0.11 to 0.01) | 0 (−0.02 to 0) |
| p=0.3 | p=0.003 | p=0.4 | ||||
| Leptin (IQR) (ng/mL) | 0.74 (−2.48 to 4.04) | 0.3 (−0.85 to 2.43) | −0.29 (−3.71 to 2.53) | −1.15 (−5.86 to 1.75) | −0.65 (−3.65 to 3.01) | −0.71 (−12.39 to 4.37) |
| p=0.63 | p=0.96 | p=0.4 | ||||
| Adiponectin (IQR) (mg/L) | 0.17 (−0.29 to 0.93) | −0.3 (−1.2 to 0.32) | 0.2 (−0.61 to 1.01) | −0.12 (−1.11 to 0.91) | 0.51 (−0.25 to 1.57) | −1.05 (−1.54 to −0.43) |
| p=0.01 | p=0.36 | p=0.035 | ||||
| LAR (IQR) (ng/µg) | 0.07 (−0.29 to 0.47) | 0.04 (−0.12 to 0.42) | −0.05 (−0.57 to 0.38) | −0.24 (−0.65 to 0.24) | −0.07 (−0.62 to 0.38) | 0.41 (−0.91 to 0.83) |
| p=0.9 | p=0.62 | p=0.2 | ||||
Responders are patients achieving a good or moderate EULAR response at week 24, whereas non-responders are those that did not.
Statistical analysis using ANCOVA model adjusted on baseline parameters.
ANCOVA, analysis of covariance; Apo, apolipoprotein; LAR, leptin/adiponectin ratio; TNFi, tumour necrosis factor inhibitor; p, p-value using ANCOVA model.